E.V. Balandina
E.V. Balandina has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrey V. Zolotarev
Samara State Medical University
2 shared publications - Elena V. Karlova
Samara State Medical University; Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky
2 shared publications - Evgeniy Zamytskiy
Samara State Medical University
2 shared publications - Dotsenko Kamila
Samara State Medical University
1 shared publication - E. V. Grishina
Samara State Medical University
1 shared publication - E. Yu. Zubkova
Eroshevsky Samara Regional Clinical Ophthalmological Hospital
1 shared publication
Latest Publications
- 8 September 2025
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 141 (4) , 60-65
Nanosecond retinal laser therapy: three years of practical experience
Objective. This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser. Material and methods. The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment. Patients with early and intermediate stages of age-related macular degeneration (AMD) were enrolled. The exclusion criteria from the study were the presence of reticular pseudodrusen, drusenoid detachment (avascular pigment epithelial detachment) measuring >1000 μm, and areas of retinal pigment epithelium (RPE) atrophy detected by optical coherence tomography (OCT). Results. After treatment, visual acuity in group 1 did not change and remained stable at 0.99, while in group 2 there was a decrease in mean uncorrected visual acuity (UCVA) from 0.98 to 0.86. In addition, OCT findings in group 1 showed no progression in 96% (41 eyes) of cases. At the same time, in 2% (1 eye) of cases, there was a significant positive trend in relation to retinal anatomy according to OCT, and in 2% (1 eye) of cases, despite some negative dynamics in retinal anatomy, there was no decrease in vision. In contrast, the disease progressed to the wet form in 19% of group 2 patients after 36 months of follow-up. According to microperimetry, retinal sensitivity in the macular area and in 2RT foci in group 1 was stable or slightly improved. There was a trend toward improved fixation on microperimetry. Conclusion. Results of the study show that after 2RT therapy the condition of the retina can stabilize or even improve, supporting the broader use of retinal laser stimulation using a nanosecond laser in patients with early forms of AMD to prevent the progression of the disease and its transition to the wet form.
- 8 September 2025
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 141 (4) , 60-65
Nanosecond retinal laser therapy: three years of practical experience
Objective. This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser. Material and methods. The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment. Patients with early and intermediate stages of age-related macular degeneration (AMD) were enrolled. The exclusion criteria from the study were the presence of reticular pseudodrusen, drusenoid detachment (avascular pigment epithelial detachment) measuring >1000 μm, and areas of retinal pigment epithelium (RPE) atrophy detected by optical coherence tomography (OCT). Results. After treatment, visual acuity in group 1 did not change and remained stable at 0.99, while in group 2 there was a decrease in mean uncorrected visual acuity (UCVA) from 0.98 to 0.86. In addition, OCT findings in group 1 showed no progression in 96% (41 eyes) of cases. At the same time, in 2% (1 eye) of cases, there was a significant positive trend in relation to retinal anatomy according to OCT, and in 2% (1 eye) of cases, despite some negative dynamics in retinal anatomy, there was no decrease in vision. In contrast, the disease progressed to the wet form in 19% of group 2 patients after 36 months of follow-up. According to microperimetry, retinal sensitivity in the macular area and in 2RT foci in group 1 was stable or slightly improved. There was a trend toward improved fixation on microperimetry. Conclusion. Results of the study show that after 2RT therapy the condition of the retina can stabilize or even improve, supporting the broader use of retinal laser stimulation using a nanosecond laser in patients with early forms of AMD to prevent the progression of the disease and its transition to the wet form.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 140 (6) , 100-106
Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema
The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab. The duration of follow-up after the loading phase ranged from 4 to 24 weeks at the time of this writing. All patients showed a pronounced anatomical improvement, and seven of the 11 experienced an increase in visual acuity. All reported subjective vision improvement, and no adverse events. These results confirm the high efficacy and safety of faricimab for nAMD and DME, both in treatment-naïve patients and those switched from other therapies.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 140 (6) , 100-106
Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema
The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab. The duration of follow-up after the loading phase ranged from 4 to 24 weeks at the time of this writing. All patients showed a pronounced anatomical improvement, and seven of the 11 experienced an increase in visual acuity. All reported subjective vision improvement, and no adverse events. These results confirm the high efficacy and safety of faricimab for nAMD and DME, both in treatment-naïve patients and those switched from other therapies.